Objective Renal adverse events associated with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have gained increasing attention in clinical practice. However, comparative real-world data regarding renal safety profiles among individual CDK4/6 inhibitors remain limited. This study aimed to characterize renal adverse...
S. Guzel, A. M. Alan, Kubilay Tay et al.· Frontiers in Pharmacology· 0 citations
Cetuximab-induced skin toxicity was independently associated with improved OS in R/M HNSCC patients treated with the EXTREME regimen, suggesting its potential role as a pharmacodynamic biomarker of cetuximab efficacy.
M. Fidan, S. Safarov, H. Abbasov et al.· Cerrahpasa Medical Journal· 0 citations
Background: Pathological complete response (pCR) following neoadjuvant systemic therapy (NST) is associated with improved outcomes in breast cancer. We evaluated the association between PET/CT-derived metabolic parameters and pCR and explored whether these associations differed according to molecular subtype. Methods:...
Z. Birsin, Mehmet Taner Bodur, S. Cebeci et al.· Diagnostics· 0 citations
In patients with HR+/HER2− metastatic breast cancer, the site of first progression after CDK4/6 inhibitor therapy may help estimate subsequent prognosis, and routinely available imaging findings may add practical value when assessing risk after CDK4/6 inhibitor failure.
Vali Aliyev, Z. Birsin, M. Günaltılı et al.· Cerrahpasa Medical Journal· 0 citations